Scinai Immunotherapeutics (NASDAQ:SCNI – Get Free Report) posted its earnings results on Monday. The company reported $0.30 earnings per share for the quarter, topping analysts’ consensus estimates of ($8.50) by $8.80, FiscalAI reports. The firm had revenue of $1.86 million for the quarter, compared to analyst estimates of $0.49 million.
Scinai Immunotherapeutics Price Performance
Scinai Immunotherapeutics stock traded down $0.01 during mid-day trading on Wednesday, reaching $0.48. 23,618 shares of the company were exchanged, compared to its average volume of 746,371. The company has a fifty day simple moving average of $1.20 and a 200-day simple moving average of $4.19. Scinai Immunotherapeutics has a 12 month low of $0.39 and a 12 month high of $13.00. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.56 and a quick ratio of 1.35. The firm has a market cap of $649,440.00, a PE ratio of 0.06 and a beta of 2.27.
Shares of Scinai Immunotherapeutics are going to reverse split on Thursday, November 19th. The 1-4 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Wednesday, November 18th.
Analyst Ratings Changes
Separately, Weiss Ratings upgraded shares of Scinai Immunotherapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research note on Wednesday, October 21st. One research analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.
View Our Latest Analysis on Scinai Immunotherapeutics
About Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) is an Israel-based clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for autoimmune and inflammatory diseases. The company’s research is centered on treatments intended to modulate disease-related immune responses while potentially limiting systemic exposure and associated side effects. Scinai’s technology platform is based on NanoAb antibody fragments, which are designed to bind specific biological targets and may be suitable for local administration.
Recommended Stories
- Five stocks we like better than Scinai Immunotherapeutics
- Aehr Test Systems Notches Another Post-Earnings Win as Sales Triple on AI Demand
- Alphabet Escalates AI Chip Rivalry With NVIDIA
- Amazon’s Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?
- 3 Stocks Wall Street Likes More Than the Market Does
Receive News & Ratings for Scinai Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scinai Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
